Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9954116 | 0.86 | PTGS2 (0.43) | ATMROCK2CREBBPALDH1A1TDP1 | |
| SCHEMBL9953430 | 0.86 | PTGS2 (0.43) | ATMROCK2CREBBPALDH1A1TDP1 | |
| SCHEMBL9953264 | 0.86 | PTGS2 (0.43) | ATMROCK2CREBBPALDH1A1TDP1 | |
| SCHEMBL28819790 | 0.81 | OPRK1 (0.48) | ATMROCK2CREBBPALDH1A1TDP1 | |
| SCHEMBL15302848 | 0.81 | OPRK1 (0.48) | ATMROCK2CREBBPALDH1A1TDP1 | |
| SCHEMBL9954004 | 0.78 | RAB9A (0.51) | ROCK2CREBBPALDH1A1NPBWR1FAAH | |
| SCHEMBL9953649 | 0.78 | RAB9A (0.51) | ROCK2CREBBPALDH1A1NPBWR1FAAH | |
| SCHEMBL10036282 | 0.78 | RAB9A (0.51) | ROCK2CREBBPALDH1A1NPBWR1FAAH | |
| SCHEMBL9954533 | 0.77 | KCNA5 (0.42) | CREBBP | |
| SCHEMBL15305627 | 0.76 | PTGS2 (0.48) | ROCK2CREBBPFAAHMETLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654752-B1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PF MEDICAMENT (FR) | 2015-05-27 | — | — | EP | disclosed |
| US-8993569-B2 | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | PIERRE FABRE MEDICAMENT (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2654752-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | Pierre Fabre Medicament (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012085001-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | KCNA4, KCNK4, KCNQ4 | ATM 4024/4885ROCK2 4425/4885CREBBP 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.